

## SPECIAL FEATURES

### CCR Pediatric Oncology Series

Complimentary access to this online-only series of articles from the AACR Childhood Cancer Predisposition Workshop:  
[clincancerres.aacrjournals.org/pediatricseries](http://clincancerres.aacrjournals.org/pediatricseries)



- e91** **Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient**  
Harriet Druker, Kristin Zelle, Rose B. McGee, Sarah R. Scollon, Wendy K. Kohlmann, Katherine A. Schneider, and Kami Wolfe Schneider
- e98** **Retinoblastoma and Neuroblastoma Predisposition and Surveillance**  
Junne Kamihara, Franck Bourdeaut, William D. Foulkes, Jan J. Molenaar, Yaël P. Mossé, Akira Nakagawara, Andreu Parareda, Sarah R. Scollon, Kami Wolfe Schneider, Alison H. Skalet, Lisa J. States, Michael F. Walsh, Lisa R. Diller, and Garrett M. Brodeur
- e107** **Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood**  
Maria Isabel Achatz, Christopher C. Porter, Laurence Brugières, Harriet Druker, Thierry Frebourg, William D. Foulkes, Christian P. Kratz, Roland P. Kuiper, Jordan R. Hansford, Hector Salvador Hernandez, Katherine L. Nathanson, Wendy K. Kohlmann, Leslie Doros, Kenan Onel, Kami Wolfe Schneider, Sarah R. Scollon, Uri Tabori, Gail E. Tomlinson, D. Gareth R. Evans, and Sharon E. Plon
- e115** **Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma**  
Jennifer M. Kalish, Leslie Doros, Lee J. Helman, Raoul C. Hennekam, Roland P. Kuiper, Saskia M. Maas, Eamonn R. Maher, Kim E. Nichols, Sharon E. Plon, Christopher C. Porter, Surya Rednam, Kris Ann P. Schultz, Lisa J. States, Gail E. Tomlinson, Kristin Zelle, and Todd E. Druley
- e123** **Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood**  
Jonathan D. Wasserman, Gail E. Tomlinson, Harriet Druker, Junne Kamihara, Wendy K. Kohlmann, Christian P. Kratz, Katherine L. Nathanson, Kristian W. Pajtler, Andreu Parareda, Surya P. Rednam, Lisa J. States, Anita Villani, Michael F. Walsh, Kristin Zelle, and Joshua D. Schiffman

## Highlights of This Issue 3227

### CCR Translations

- 3229** **The Microbiota: A New Variable Impacting Cancer Treatment Outcomes**  
Jessica L. Fessler and Thomas F. Gajewski  
*See related article, p. 3263*

### Reviews

- 3232** **Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair**  
 Aimee Bence Lin, Samuel C. McNeely, and Richard P. Beckmann
- 3241** **The Promise of Targeting Macrophages in Cancer Therapy**  
J. Martin Brown, Lawrence Recht, and Samuel Strober
- 3251** **Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors**  
 Debu Tripathy, Aditya Bardia, and William R. Sellers

### PERSPECTIVE

- 3263** **Can Consideration of the Microbiome Improve Antimicrobial Utilization and Treatment Outcomes in the Oncology Patient?**  
Jessica R. Galloway-Peña, Robert R. Jenq, and Samuel A. Shelburne  
*See related commentary, p. 3229*

### CANCER THERAPY: CLINICAL

- 3269** **First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies**  
Gregory L. Beatty, Peter J. O'Dwyer, Jason Clark, Jack G. Shi, Kevin J. Bowman, Peggy A. Scherle, Robert C. Newton, Richard Schaub, Janet Maleski, Lance Leopold, and Thomas F. Gajewski

# Table of Contents

- 3277** Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial



Vincent Chung, Aaron S. Mansfield, Fadi Braiteh, Donald Richards, Henry Durivage, Richard S. Ungerleider, Francis Johnson, and John S. Kovach

- 3285** Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients

Philippe O. Gannon, Petra Baumgaertner, Alexandre Huber, Emanuela M. Iancu, Laurène Cagnon, Samia Abed Maillard, Hélène Maby-El Hajjami, Daniel E. Speiser, and Nathalie Rufer

- 3297** Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Yongxian Hu, Zhao Wu, Yi Luo, Jimin Shi, Jian Yu, Chengfei Pu, Zuyu Liang, Guoqing Wei, Qu Cui, Jie Sun, Jing Jiang, Jue Xie, Yamin Tan, Wanmao Ni, Jifang Tu, Jinping Wang, Aiyun Jin, Hao Zhang, Zhen Cai, Lei Xiao, and He Huang

- 3307** Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, Noopur Raje, Sundar Jagannath, Paul Richardson, Parameswaran Hari, Robert Orlowski, Jeffrey G. Supko, David Tamang, Min Yang, Simon S. Jones, Catherine Wheeler, Robert J. Markelewicz, and Sagar Lonial

- 3316** LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab

Laura Bonanno, Angela De Paoli, Elisabetta Zulato, Giovanni Esposito, Fiorella Calabrese, Adolfo Favaretto, Antonio Santo, Alessandro Del Conte, Marco Chilosi, Francesco Oniga, Gabriella Sozzi, Massimo Moro, Francesco Ciccarese, Giorgia Nardo, Roberta Bertorelle, Cinzia Candiotti, Gian Luca De Salvo, Alberto Amadori, PierFranco Conte, and Stefano Indraccolo

## PERSONALIZED MEDICINE AND IMAGING

- 3325** Variants in *WFS1* and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity

Heather E. Wheeler, Eric R. Gamazon, Robert D. Frisina, Carlos Perez-Cervantes, Omar El Charif, Brandon Mapes, Sophie D. Fossa, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Christian Kollmannsberger, Jeri Kim, Taisei Mushiroda, Michiaki Kubo, Shirin Ardeshir-Rouhani-Fard, Lawrence H. Einhorn, Nancy J. Cox, M. Eileen Dolan, and Lois B. Travis

- 3334** Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways

Jia Wu, Yi Cui, Xiaoli Sun, Guohong Cao, Bailiang Li, Debra M. Ikeda, Allison W. Kurian, and Ruijiang Li

- 3343** Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy

Kwanghee Kim, Hanwen Zhang, Stephen La Rosa, Sylvia Jebiwott, Pooja Desai, Simon Kimm, Avigdor Scherz, Joseph A. O'Donoghue, Wolfgang A. Weber, and Jonathan A. Coleman

- 3352** Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients



Luciano Castiello, Marianna Sabatino, Jiaqiang Ren, Masaki Terabe, Hanh Khuu, Lauren V. Wood, Jay A. Berzofsky, and David F. Stronck

- 3365** Tumor *BRCA1* Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

Anosheh Afghahi, Kirsten M. Timms, Shaveta Vinayak, Kristin C. Jensen, Allison W. Kurian, Robert W. Carlson, Pei-Jen Chang, Elizabeth Schackmann, Anne-Renee Hartman, James M. Ford, and Melinda L. Telli

## CANCER THERAPY: PRECLINICAL

- 3371** PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses

Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt McClain, Gregory D. Ayers, Mark C. Kelley, Melinda Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, and Ann Richmond

# Table of Contents

- 3385** Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia  
Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Noguera González, Antonio Cavazos, Rongqing Pan, Hong Mu, Sa A. Wang, Jin Zhou, Gheath Al-Atrash, Stefan O. Ciurea, Mike Rettig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, and Marina Konopleva
- 3396** Immunization against HIF-1 $\alpha$  Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells *In Vivo*  
Denise L. Cecil, Meredith Slota, Megan M. O'Meara, Benjamin C. Curtis, Ekram Gad, Yushe Dang, Daniel Herendeen, Lauren Rastetter, and Mary L. Disis
- 3405** Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in *BRCA1/2*-wild-type Triple-Negative Breast Cancer  
Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali A. Mostafa, and David M. Goldenberg
- 3416** A Novel Murine GTR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist  
Rebecca Leyland, Amanda Watkins, Kathy A. Mulgrew, Nicholas Holowecyj, Lisa Bamber, Natalie J. Tighe, Emily Offer, John Andrews, Li Yan, Stefanie Mullins, Michael D. Oberst, Jane Coates Ulrichsen, David A. Leinster, Kelly McGlinchey, Lesley Young, Michelle Morrow, Scott A. Hammond, Philip Mallinder, Athula Herath, Ching Ching Leow, Robert W. Wilkinson, and Ross Stewart
- 3442** STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma  
Yukihiro Otaka, Susumu Rokudai, Kyoichi Kaira, Michiru Fujieda, Ikuko Horikoshi, Reika Iwakawa-Kawabata, Shinji Yoshiyama, Takehiko Yokobori, Yoichi Ohtaki, Kimihiro Shimizu, Tetsunari Oyama, Jun'ichi Tamura, Carol Prives, and Masahiko Nishiyama
- 3453** Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer  
Jayanta Chatterjee, Wei Dai, Nor Haslinda Abd Aziz, Pei Yun Teo, John Wahba, David L. Phelps, Christian J. Maine, Lynsey M. Whilding, Roberto Dina, Giorgia Trevisan, Kirsty J. Flower, Andrew J.T. George, and Sadaf Ghaem-Maghami
- 3461** HMGA2-FOXL2 Axis Regulates Metastases and Epithelial-to-Mesenchymal Transition of Chemoresistant Gastric Cancer  
Jiaqiang Dong, Rui Wang, Gui Ren, Xiaowei Li, Jingbo Wang, Yi Sun, Jie Liang, Yongzhan Nie, Kaichun Wu, Bin Feng, Yulong Shang, and Daiming Fan
- LETTER TO THE EDITOR**
- 3474** FDG PET and FES PET Predict PFS on Endocrine Therapy—Letter  
David Groheux and François Bénard
- 3475** FDG PET and FES PET Predict PFS on Endocrine Therapy—Response  
Brenda F. Kurland, Hannah M. Linden, and David A. Mankoff

## BIOLOGY OF HUMAN TUMORS

- 3428** Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer  
Ke Chen, Haibing Xiao, Jin Zeng, Gan Yu, Hui Zhou, Chunhua Huang, Weimin Yao, Wei Xiao, Junhui Hu, Wei Guan, Lily Wu, Jiaoti Huang, Qihong Huang, Hua Xu, and Zhangqun Ye




AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# Table of Contents

## ABOUT THE COVER

The cover shows a section of a PyMT breast tumor treated with the pan PI3K inhibitor BKM120 (30 mg/kg daily) and PD-1-blocking antibody (100  $\mu$ g twice a week). H&E staining reveals an extensive infiltration of immune cells into the treated tumors, which was associated with reduction in tumor growth and was not observed in control tumors. For details, see the article by Sai and colleagues on page 3371 of this issue.



# Clinical Cancer Research

**23 (13)**

*Clin Cancer Res* 2017;23:e123-3475.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/23/13>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/13>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.